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STUDY PROTOCOL Open Access
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Abstract
Background: The estimated annual global burden of miscarriage is 33 million out of 210 million pregnancies. Many
women undergoing miscarriage have surgery to remove pregnancy tissues, resulting in miscarriage surgery being
one of the most common operations performed in hospitals in low-income countries. Infection is a serious consequence
and can result in serious illness and death. In low-income settings, the infection rate following miscarriage surgery has
been reported to be high.
Good quality evidence on the use of prophylactic antibiotics for surgical miscarriage management is not available. Given
that miscarriage surgery is common, and infective complications are frequent and serious, prophylactic antibiotics may
offer a simple and affordable intervention to improve outcomes.
Methods: Eligible patients will be approached once the diagnosis of miscarriage has been made according to local
practice. Once informed consent has been given, participants will be randomly allocated using a secure internet facility
(1:1 ratio) to a single dose of oral doxycycline (400 mg) and metronidazole (400 mg) or placebo. Allocation will be
concealed to both the patient and the healthcare providers. A total of 3400 women will be randomised, 1700 in each
arm. The medication will be given approximately 2 hours before surgery, which will be provided according to local
practice. The primary outcome is pelvic infection 2 weeks after surgery. Women will be invited to the hospital for a
clinical assessment at 2 weeks. Secondary outcomes include overall antibiotic use, individual components of the primary
outcome, death, hospital admission, unplanned consultations, blood transfusion, vomiting, diarrhoea, adverse events,
anaphylaxis and allergy, duration of clinical symptoms, and days before return to usual activities. An economic evaluation
will be performed to determine if prophylactic antibiotics are cost-effective.
(Continued on next page)
* Correspondence: d.m.lissauer@bham.ac.uk
1Institute of Metabolism and Systems Research, University of Birmingham,
Birmingham B15 2TT, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lissauer et al. Trials  (2018) 19:245 
https://doi.org/10.1186/s13063-018-2598-3
(Continued from previous page)
Discussion: This trial will assess whether a single dose of doxycycline (400 mg) and metronidazole (400 mg) taken orally
2 hours before miscarriage surgery can reduce the incidence of pelvic infection in women up to 2 weeks after
miscarriage surgery.
Trial registration: Registered with the ISRCTN (international standard randomised controlled trial number)
registry: ISRCTN 97143849. (Registered on April 17, 2013).
Keywords: Miscarriage, miscarriage surgery, pelvic infection, antibiotics, placebo-controlled trial, randomised
controlled trial, low-income countries, economic evaluation
Background
The estimated annual global burden of miscarriage is 33
million out of 210 million pregnancies [1, 2]. The major-
ity of women with a miscarriage will undergo surgery,
performed to remove pregnancy tissues from the uterus
[3]. In many hospitals in low-income countries, miscar-
riage surgery is one of the most common operations
performed; for example, at Queen Elizabeth Central
Hospital, Malawi, an average of 156 suction evacuations
for miscarriage are carried out each month, representing
68% of gynaecology admissions [4].
Infection is a serious consequence of miscarriage sur-
gery. The data available from high-income countries
found that it occurred in up to 6% of women following
surgical management of miscarriage [5, 6]. In low-
income settings, the infection rate after miscarriage
surgery has been reported to be up to 30% [7]. Infection
after miscarriage can result in serious illness and death,
as well as long-term consequences from pelvic scarring,
increased rates of ectopic pregnancy and infertility.
Ectopic pregnancies can result in death from severe
haemorrhage, and infertility has profound social and
economic effects that go beyond childlessness, with
women bearing the brunt of the burden [8].
For surgical termination of pregnancy, the standard
practice is to provide prophylactic antibiotics before or
during surgery as there is evidence of benefit for this
intervention [9] and unanimous endorsement from policy-
makers and practitioners [9–13]. However, evidence is in-
sufficient for miscarriage management and therefore,
unsurprisingly, policymakers do not recommend, and
practitioners do not consistently provide, prophylactic an-
tibiotics during surgery. However, given that miscarriage
surgery is common, and infective complications are fre-
quent and serious, prophylactic antibiotics, if found to be
effective in a well-conducted and adequately powered trial,
may offer a simple and affordable intervention to reduce
the burden of disease in low-income countries.
Methods/Design
Aims and objectives
The primary objective is to test the hypothesis that, in
women having miscarriage surgery, pre-surgery
prophylactic antibiotics (oral doxycycline 400 mg and
oral metronidazole 400 mg) reduce the risk of pelvic in-
fection within 14 days of surgery. In cases where partici-
pants do not return for follow-up within this period,
follow-up until 28 days will be acceptable.
The secondary objectives are to test whether prophy-
lactic antibiotics result in a reduction in maternal mor-
tality, duration of clinical symptoms, hospital admission,
unplanned consultations and overall antibiotic use. We
will also examine the individual components of the pri-
mary outcome and test the hypothesis that prophylactic
antibiotics, compared to placebo, do not incur serious
adverse effects to the mother.
We will explore differential effects of antibiotic
prophylaxis in the subgroups of (1) type of surgery
(manual vacuum aspiration, suction curettage or sharp
curettage), (2) type of miscarriage (incomplete or
missed), (3) gestational age (< 12 weeks or ≥ 12 weeks,
when known), (4) HIV status (positive or negative, when
results available), (5) time between administration of an-
tibiotics and surgery, (6) country and sites, and (7) rural
or urban residence. In addition, we will perform an eco-
nomic evaluation to determine if prophylactic antibiotics
are cost-effective.
Design and setting
The AIMS trial is a randomised, double blind, placebo-
controlled multicentre study, with a health economic
evaluation. The trial is set in a diverse range of hospitals
across four countries, namely in Malawi at Queen
Elizabeth Central Hospital, Zomba Central Hospital and
Kamuzu Central Hospital; in Uganda at Mbale Regional
Referral Hospital and Soroti Regional Referral Hospital; in
Tanzania at Bagamoyo District Hospital, Mwananyamala
Hospital and St Francis Hospital; and in Pakistan at Aga
Khan University Main Hospital, Kharader Hospital,
Garden Hospital, Hyderabad Hospital and Karimabad
Hospital.
These participating countries were selected as this is a
clinical problem that is of particular importance in low-
and middle-income countries. Final country selection was
based on the need for generalisability of the findings,
prevalence of miscarriage surgery in these countries,
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importance of the clinical question in the participating
country, existing research links, and research infrastruc-
ture to appropriately deliver the study to a high quality.
Participants
The AIMS trial will include women with a spontaneous
miscarriage under 22 weeks gestation undergoing surgi-
cal evacuation of the uterus (by manual vacuum aspir-
ation, suction curettage or sharp curettage) that are
willing and able to give informed consent, and are
undergoing their first surgical evacuation in the current
pregnancy (Fig. 1). Women having induced abortion of
pregnancy, or with a septic miscarriage, evidence of in-
fection or current febrile illness (temperature above
38 ºC) will be excluded. Women with an allergy or other
contraindication to either of the antibiotics, or using an-
tibiotics currently or within the 7 days preceding surgi-
cal evacuation, will also be excluded, as will women with
conditions requiring immediate care, e.g. severe haemor-
rhage, women under 16 years of age or women requiring
further surgical evacuation after the first surgical evacu-
ation for the current pregnancy (multiple evacuations
for the same pregnancy will not be included).
Potentially eligible patients will be approached in an
adequate setting (i.e. outpatient clinics, wards, clinical
assessment areas) and informed about the trial by an ap-
propriately trained researcher or care provider. After all
eligibility criteria has been confirmed, consent has been
obtained and all baseline data gathered, participants will
be randomised online via a secure internet facility to en-
able the allocation to remain concealed to the research
staff and the care providers, as well as the participants,
in a 1:1 ratio through an Integrated Trial Management
System, to the investigational medicinal product or the
placebo. Unblinding will only be possible by contacting
the clinical trials unit. A minimisation procedure using a
computer-based algorithm will be used to avoid chance
imbalances in important stratification variables. Strata
used in the minimisation will be age (below 35, or
35 years and above), gestation (below 12 weeks, or
12 weeks and above, or when the gestation is unclear),
the type of miscarriage (either incomplete or missed),
and HIV status (positive, proven negative, or unknown).
Study intervention and comparison
The investigational medicinal products (IMPs) are doxy-
cycline, as four 100 mg doxycycline hyclate encapsulated
tablets, and metronidazole, as one 400 mg encapsulated
tablet [14, 15]. The placebo tablets are encapsulated
microcrystalline cellulose in the same format as the
IMPs, identical in colour, shape and weight, produced
and distributed by Sharp Clinical UK. Both healthcare
provider and participant will be blinded to the allocation.
The study medications will be taken approximately 2
hours before surgery. The IMP will be administered,
with consent, under the direct observation of the clin-
ician or researcher consenting the patient for the trial.
Therefore, we do not anticipate compliance to be an
issue unless the patient choses to withdraw their consent
between randomisation and the IMP being taken. The
choice of antibiotics was made after a careful review of
the existing literature, a survey of preference, availability
and affordability in the partner countries, and a review
of other related evidence from induced abortion guide-
lines. Doxycycline is active against a broad range of
Gram-positive and Gram-negative aerobic bacteria,
including staphylococci, streptococci, and enteric
Gram-negative bacteria. It is also active against
Chlamydia trachomatis and Neisseria gonorrhoeae.
Metronidazole is effective against anaerobic bacteria.
Doxycycline is associated with a substantially lower
risk of life-threatening anaphylaxis compared with co-
amoxiclav. Both of the study medicines are commonly
used in low-income settings, and have low adverse event
Fig. 1 Participant flow through trial
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profiles. There is an extremely low risk of anaphylaxis,
which was one of the reasons for the choice of these
agents. However, should an anaphylactic reaction occur,
all sites have facilities to manage this.
The use of other non-trial medications is at the discre-
tion of the care-providing clinicians. Unblinding will
only be performed in the event of a medical emergency
in which treatment of the emergency requires knowledge
of the actual drug received.
Follow-up
Trial participants will be given multiple easy access
routes to contact the research and clinical teams to re-
port issues and seek advice and care. Women contacting
the study or research team will be reviewed promptly.
Reimbursement for potential telephone and transport
costs will be offered to participants. Non-attendance at
follow-up clinics will prompt telephone calls or others
means of contacting the participant, which will be
agreed at recruitment. If possible, contact will be made
with the participant prior to the clinic to remind them
through, for example, telephone calls or SMS text mes-
sages to prompt the reporting of any infection or other
adverse events and follow-up clinic attendance.
Withdrawal from study
A participant can be withdrawn from the trial if, in the
opinion of the investigator, it is medically necessary.
With premature withdrawal from the study, the study
personnel will make every effort to obtain, and record,
information about the reasons for discontinuation and
any adverse events and to perform all safety assessments.
A patient may voluntarily withdraw from participation
in this study at any time. If the patient does not return
for a scheduled visit, we will try to contact her. We will
aim to document the reason for withdrawal and, when
possible, all safety assessments will be performed. If a
patient explicitly withdraws consent to have data re-
corded, their decision will be respected and recorded on
the trial database. All communication surrounding the
withdrawal will be noted in the patient’s records and no
further data will be completed for that patient.
Statistical analysis
The primary outcome is pelvic infection within 14 days
of surgery. At the commencement of the study pelvic
infection was defined (based on the CDC criteria and
criteria used in previous studies) as two or more of (1)
purulent vaginal discharge, (2) pyrexia > 38.0 °C, (4)
uterine tenderness on examination and (4) a white cell
count > 12 × 109/L [14], with no other recognised cause
of infection upon history taking and examination by the
assessing clinician and/or study team (Table 1).
An amendment was made to these criteria, after recruit-
ment commencement, but without reference to study
data, as it was observed by the examining clinicians (who
were blinded to treatment allocation) that, for some
participants, whilst only a single feature of pelvic infection
was present, the symptoms were of sufficient severity that,
in their clinical judgement, there was a need to provide
treatment. After discussion with the independent trial
steering committee it was decided that the diagnostic
criteria by which pelvic infection was defined should be
adjusted. Following this amendment, pelvic infection was
diagnosed if the patient had two or more of (1) purulent
vaginal discharge, (2) pyrexia > 38.0 °C, (3) uterine tender-
ness on examination and (4) a white cell count > 12 × 109/L
[16], with no other recognised cause of infection upon
history taking and examination by the assessing clinician
and/or study team, or one of the above features, with a
clinically identified need to administer antibiotics for the
treatment of presumed pelvic infection (Table 1: primary
outcome measure ascertainment). The latter pragmatic
criteria will be reported as the primary outcome, but the
more specific strict clinical criteria for diagnosis of pelvic
infection will also be clearly reported.
In cases where participants do not return for follow-
up within the specified period of 2 weeks, follow-up
until 28 days will be acceptable.
The secondary outcomes are overall general antibiotic
use (not specifically for pelvic infection), each component
of the primary outcome, death, hospital admission,
unplanned consultations, blood transfusion, vomiting,
diarrhoea, adverse events, anaphylaxis and allergy, duration
of clinical symptoms (pain, additional analgesia, vaginal
bleeding), and days before return to usual daily activities.
Table 1 Primary outcome measure ascertainment
Purulent vaginal
discharge
Pyrexia Tenderness White cell count
Definition Yellow, green, or
offensive discharge
> 38.0 °C measured by
infrared ear thermometry
Defined as a finding on examination of either
(1) direct tenderness of the uterus, or (2) tenderness
on displacement of the uterus, or (3) tenderness of
the parametrium or (4) tender adnexal mass
White cell count
greater than 12 × 109/L
Excluded from the
definition
Clear vaginal
discharge
Upper abdominal pain
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We are proactively seeking evidence of adverse events.
Each participant will be asked, at each trial visit or inter-
view, about hospitalisations, consultations with other
medical practitioners, disability or incapacity, or any
other adverse events.
The analysis will be by intention-to-treat. The risk ratio
of women with pelvic infection in the active arm to the pla-
cebo arm will be calculated. This estimate will be adjusted
for the minimisation variables although an unadjusted esti-
mate will also be calculated as a sensitivity analysis.
In the first instance, analysis will be completed on re-
ceived data only, with every attempt made to gather data
on all subjects randomised, irrespective of compliance
with the treatment protocol. To test the robustness of
this initial analysis with respect to any missing data,
missing responses will be simulated using a multiple im-
putation approach as a sensitivity analysis. Further sensi-
tivity analysis will be performed assuming all non-
responders had a pelvic infection.
Seven pre-specified subgroup analyses are planned to
assess differential effects of antibiotic prophylaxis in (1)
type of surgery (manual vacuum aspiration, suction cur-
ettage or sharp curettage; sharp curettage is associated
with a higher incidence of pelvic infection when
compared to suction curettage [3], so a greater effect of
antibiotic prophylaxis may be seen in the sharp curettage
group); (2) type of miscarriage (incomplete or missed;
incomplete miscarriage may be associated with a higher
incidence of pelvic infection when compared to missed
miscarriage [3]); (3) gestational age (< 12 weeks or ≥
12 weeks, when known; pregnancies of a greater gesta-
tional age may have a higher incidence of pelvic infec-
tion due to the additional complexities involved with the
surgical procedure [3]); (4) HIV status (positive or nega-
tive, when results are available; participants that are HIV
positive may be more likely to experience pelvic infec-
tion as they may be immunocompromised); (5) by time
between administration of antibiotics and surgery (a re-
duced time interval between antibiotic administration
and surgery, than that specified in the protocol, may re-
sult in a reduction in bio-availability and thus in effect
reduction; the optimal maximum duration however is
unclear); (6) by country and sites; and (7) rural or urban
residence (the potential direction of effect is unclear in
sub-group analyses (6) and (7)).
We will randomise 3400 women in total, which will
give 90% power to detect a relative risk reduction of 0.4
(an RR of 0.6) (type I error rate, P = 0.05). A meta-
analysis of 18 studies of prophylactic antibiotics used for
induced abortion surgery was conducted to inform these
calculations and found a pooled RR of 0.60 (95% CI 0.
48–0.74) for the reduction of pelvic infection. We calcu-
lated sample sizes to detect this size of difference using
various scenarios for the baseline risk (varying from 3%
to 10%). The best available data for pelvic infection rates
specific to spontaneous miscarriage originate from stud-
ies in the UK and USA, demonstrating a risk of pelvic
infection of up to 6%; the risk of pelvic infection is likely
to be higher in low-income countries, yet even for a
baseline risk of, the 5% sample size of 3400 will provide
over 80% power to detect a difference in primary out-
come. Further sensitivity analysis will be performed as-
suming all non-responders had a pelvic infection.
Interim analyses of principal safety and effectiveness
endpoints will be conducted on behalf of an independent
Data Monitoring Committee (DMC). These will be con-
sidered together with a report of serious adverse events. A
pragmatic approach to stopping rules was suggested by
the DMC members with respect to interpreting the results
of any interim analysis. Appropriate criteria of proof will
therefore not be specified precisely, but an interim analysis
difference equating to P < 0.001 (similar to a Haybittle–
Peto boundary) may be needed to justify halting, or modi-
fying, of the study prematurely. This criterion has the
practical advantage that the exact number of interim ana-
lyses would be of little importance and there would only
be minimal inflation of any overall type-I error rate re-
gardless of how many interim analyses are performed, so
no exact schedule needs to be proposed.
Health economic evaluation
The economic evaluation will determine the relative
cost-effectiveness of antibiotic prophylaxis in the surgical
management of miscarriage compared to the current
practice without antibiotic prophylaxis. All resource use
data will be prospectively collected using case report
forms completed on at least one occasion prior to dis-
charge after surgery, at every contact during the follow-
up period, daily whilst an inpatient, and at final assess-
ment. Resource use information will be employed to es-
timate the costs associated with the additional use of
antibiotics in all participating centres. This will include
antibiotics and other medications related to pain, allergy,
diarrhoea, vomiting, nausea, malaria and fever as well as
inpatient stays, outpatient visits, laboratory examinations
and treatment of relevant complications, such as haem-
orrhage requiring blood transfusion, repeat uterine
evacuation and anaphylaxis. Unit cost data will be ob-
tained from the International Drug Price Indicator
Guide [17], the World Health Organization (WHO-
CHOICE) [16] and other secondary sources, and will be
adjusted to 2016 US Dollars. Given the short time hori-
zon, no discounting will be applied to costs. An incre-
mental cost-effectiveness analysis will be conducted
from a healthcare provider perspective based on the out-
come of cost per pelvic infection avoided within 2 weeks
from surgery using established health economic methods
for multinational trials [18, 19]. The uncertainty around
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cost-effectiveness point estimates will be presented using
a cost-effectiveness acceptability frontier [20]. Sensitivity
analyses will be performed to explore the robustness of
the study findings to plausible variations in key values.
Conduct and monitoring of the trial
The Birmingham Clinical Trials Unit is responsible for
the coordination of the trial; it is a fully registered UK
Clinical Research Collaboration clinical trials unit, and
provides a robust quality management system to ensure
good practice in the conduct and statistical analysis of
the project. The trial is being conducted in accordance
with the ethical principles that have their origin in the
Declaration of Helsinki, 1996, namely the principles of
Good Clinical Practice. The trial was not initiated at
each site before full approval from the UK Research Eth-
ics Committee, and the respective national Research
Ethics Committee and local regulatory bodies was re-
ceived. All AIMS investigators are responsible for (1)
maintaining the protocol of the trial as described in this
document, (2) helping healthcare professionals to ensure
the study participants receive appropriate care through-
out the period of research enrolment, (3) protecting the
integrity and confidentiality of clinical and other records
and data that may be generated by the research, and (4)
reporting any failures in these respects, adverse drug re-
actions and other events or suspected misconduct
through the appropriate systems (Additional file 1).
Accrual is monitored against set targets. If a centre is
not meeting its recruitment targets then the Trial
Management Group will work with the local Principal
Investigator and team to identify barriers to recruitment
and solutions to any problems. Communication between
the centres will enable the spread of good practice and
experience between sites. Follow-up requirements are
carefully explained to each participant. Written informa-
tion is also provided in the form of the “follow-up card”
(Additional file 3). Trial participants are given multiple
easy access routes to contact the research and clinical
teams to report issues and seek advice and care. Women
contacting the study or research team are reviewed
promptly. Reimbursement for potential telephone and
transport costs are offered to participants. Non-
attendance at follow-up clinics prompts telephone calls
or other means of contacting the participant, which are
agreed at recruitment. If possible, contact is made with
the participant prior to the clinic to provide them a re-
minder through, for example, telephone calls or SMS
text messages to prompt the reporting of any infection
or other adverse events and follow-up clinic attendance.
Details about complaints are provided in the patient in-
formation sheet. Management of complaints is the re-
sponsibility of the local Principal Investigator and should
follow any locally available procedures before reporting
to the trial management group.
Collected data are stored on secure computers. The
necessary trial data is encrypted. Electronic data is
backed up every 24 h to both local and remote media in
encrypted format. Paper-based data (e.g. signed consent
forms) are kept locked at each site. Individual participant
information obtained as a result of this study is consid-
ered confidential. Each participant is allocated a unique
study number at recruitment. All documents use this as
the identifier. All data will be analysed and reported in
summary format. No individual will be identifiable.
The Trial Steering Committee provides overall super-
vision of the trial and ensures that it is being conducted
in accordance with the principles of Good Clinical
Practice and other relevant regulations. The DMC reviews
the accruing trial data and assesses the safety data to make
recommendations on whether the trial should continue,
be modified or be terminated. In addition, the DMC also
examines effectiveness data to determine if continuation
of the trial is unethical, and examines the recruitment, loss
to follow-up, compliance and protocol violation data to
ascertain if continuation of the trial is futile.
Discussion
If found beneficial, antibiotics will reduce immediate
complications such as sepsis, the need for further opera-
tions and death, as well as long-term complications such
as subfertility, pelvic pain and ectopic pregnancy.
Furthermore, if beneficial, their use would result in a re-
duction in the financial costs borne by women who have
had miscarriages, including reduced loss of earnings and
reduced treatment, transport and subsistence costs asso-
ciated with infective complications, and the long-term
health consequences such as chronic pelvic pain.
Chronic pelvic pain is a recognised complication of in-
fective complications after miscarriage and is known to
have a major impact on work productivity.
If found to be of no benefit, then guidance to avoid
prescribing in this situation could be strengthened, redu-
cing unnecessary antibiotic usage, risks of allergy and
antimicrobial resistance.
This double-blind randomised placebo controlled trial
addresses the key clinical question of whether prophylac-
tic doxycycline (400 mg) and metronidazole (400 mg),
prior to miscarriage surgery, can prevent pelvic infec-
tion. We anticipate that the findings from this definitive,
multicountry study, will inform international practice.
Trial status
The protocol was submitted on April 7, 2017, at which
point all countries were still recruiting to the trial.
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Management Group and Trial Steering Committee, and is likely to include the
trial manager, chief investigator, statistician and high-accruing investigators.
Individual researchers must not publish data concerning their patients until the
primary study question has been answered, and explicit permission has been
granted by the Trial Management Group.
A dissemination plan has been formulated to lead to the dissemination of
our findings and, if appropriate, rapid implementation. We would hope to
implement change to national and international guidelines and see clinicians
altering their practice.
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